ClinicalTrials.gg
TerminatedNCT00808210Updated Nov 6, 2020Results posted

A Study to Evaluate Ocrelizumab in Combination With Methotrexate Compared With Infliximab Plus Methotrexate in Patients With Active Rheumatoid Arthritis Currently Responding Inadequately to Etanercept or Adalimumab

A Phase 2 interventional study of Infliximab and Methotrexate in Rheumatoid Arthritis, sponsored by Genentech, Inc.. Terminated at 53 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-06.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 2, Interventional, and Treatment

Why this study was terminated
Based on analysis of results and consideration of available treatments, the overall benefit to risk profile of ocrelizumab was not favorable in RA.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
28
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche — 2 open to participants now, 2 under way, none of them phase 3. Arthritis, Rheumatoid · Hoffmann-La Roche.

Enrollment
118th of 141
28 · median 132
Started
2009
with 21 others
Phase 2
20 of 219
2 open now
Registered
54th of 219
by date

Among the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, this one is the 118th largest by enrollment of the 141 interventional ones that give a count, is one of 22 that started in 2009, is one of 20 in phase 2, and was the 54th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

2 of the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, or all of them as a file.
02

Study summary

This is a Phase II, randomized, active-controlled, double-blind, double-dummy, parallel-group, multicenter study in the United States enrolling patients with active RA. The study will enroll approximately 290 patients at approximately 130 sites.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • RA
  • Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >= 18 years
  • Current treatment for RA on an outpatient basis
  • Active disease
  • Currently receiving 50 mg etanercept subcutaneously (SC) every week or 40 mg adalimumab SC every other week.
  • Considered by Investigator to be a primary non-responder to their first anti-TNFα treatment for efficacy reasons

Exclusion criteria

Exclusion Criteria:

  • Rheumatic disease other than RA, or significant systemic involvement secondary to RA
  • History of, or current, inflammatory joint disease other than RA (e.g., gout, reactive arthritis, psoriatic arthritis, seronegative spondyloarthropathy, Lyme disease) or other systemic autoimmune disorder (e.g., systemic lupus erythematosus, inflammatory bowel disease, scleroderma, inflammatory myopathy, mixed connective tissue disease or other overlap syndrome)
  • Previous treatment with a any biologic therapy for RA (including products with the exception of etanercept or adalimumab
  • Treatment with more than one prior anti-TNFα therapy
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Ocrelizumab 200mg

    Participants received two intravenous (IV) infusions of 200 mg ocrelizumab administered on Day 1 and Day 15 and placebo IV infliximab infusions administered on Day 1, Day 15, Week 6, and Week 14. In addition to the study medication, all patients were to receive methotrexate at a stable dose of 7.5-25 mg/week and folic acid or equivalent at a dose of 5 mg/week to minimize methotrexate toxicity.

    Drug: Methotrexate · Drug: Methylprednisolone · Drug: Ocrelizumab · Drug: Placebo

  • Active comparator
    Infliximab 5mg/kg

    Participants received four IV infusions of 5 mg/kg infliximab administered on Day 1, Day 15, Week 6, and Week 14 and placebo ocrelizumab infusions administered on Day 1 and Day 15. In addition to the study medication, all patients were to receive methotrexate at a stable dose of 7.5-25 mg/week and folic acid or equivalent at a dose of 5 mg/week to minimize methotrexate toxicity.

    Drug: Infliximab · Drug: Methotrexate · Drug: Methylprednisolone · Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in DAS28(ESR) at Week 20

    Time frame: Week 20

Secondary outcomes

  1. Percentage of Participants With Clinical Response of 20% According to ACR Criteria

    Time frame: Baseline up to 30 months

  2. Percentage of Participants With Clinical Response of 50% According to ACR Criteria

    Time frame: Baseline up to 30 months

  3. Percentage of Participants With Clinical Response of 70% According to ACR Criteria

    Time frame: Baseline up to 30 months

  4. European League Against Rheumatism (EULAR) Response Rates

    Time frame: Baseline up to 30 months

  5. Change in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score

    Time frame: Baseline up to 30 months

  6. Change in Fatigue Visual Analog Scale Score (VAS)

    Time frame: Baseline up to 30 months

  7. Percentage of Participants With Adverse Events (AEs)

    Time frame: Baseline up to 30 months

07

Results

Posted Nov 6, 2020
Limitations and caveats
At the time of study termination the scope of the statistical analyses was reduced and limited to evaluation of the safety profile.

Participant flow

Study Period + 48 Weeks of Follow-up
Participant flow — Study Period + 48 Weeks of Follow-up
MilestoneOcrelizumab 200mgInfliximab 5mg/kg
Started1513
Completed64
Not completed99
Withdrew: Sponsor decision to terminate study37
Withdrew: Other reasons outside sponsor decision62
Double-Blind TX Period
Participant flow — Double-Blind TX Period
MilestoneOcrelizumab 200mgInfliximab 5mg/kg
Started1513
Completed1310
Not completed23
Withdrew: Adverse event01
Withdrew: Sponsor decision to terminate study11
Withdrew: Other reasons outside sponsor decision11
Open Label Ocrelizumab Treatment Period
Participant flow — Open Label Ocrelizumab Treatment Period
MilestoneOcrelizumab 200mgInfliximab 5mg/kg
Started94
Completed00
Not completed94
Withdrew: Sponsor decision to terminate study94

Outcome measures

PrimaryChange From Baseline in DAS28(ESR) at Week 20
Time frame:
Week 20

No measurements were reported for this outcome.

SecondaryPercentage of Participants With Clinical Response of 20% According to ACR Criteria
Time frame:
Baseline up to 30 months

No measurements were reported for this outcome.

SecondaryPercentage of Participants With Clinical Response of 50% According to ACR Criteria
Time frame:
Baseline up to 30 months

No measurements were reported for this outcome.

SecondaryPercentage of Participants With Clinical Response of 70% According to ACR Criteria
Time frame:
Baseline up to 30 months

No measurements were reported for this outcome.

SecondaryEuropean League Against Rheumatism (EULAR) Response Rates
Time frame:
Baseline up to 30 months

No measurements were reported for this outcome.

SecondaryChange in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score
Time frame:
Baseline up to 30 months

No measurements were reported for this outcome.

SecondaryChange in Fatigue Visual Analog Scale Score (VAS)
Time frame:
Baseline up to 30 months

No measurements were reported for this outcome.

SecondaryPercentage of Participants With Adverse Events (AEs)
Time frame:
Baseline up to 30 months
Reported as:
Number · Percentage of Participants
Percentage of Participants With Adverse Events (AEs)
Percentage of ParticipantsOcrelizumab 200mgInfliximab 5mg/kg
Percentage of Participants With Adverse Events (AEs)78.976.9

Adverse events

Collected over Baseline up to 43 months. Non-serious events are listed at a 0.05% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ocrelizumab 200mg0/19 (0%)2/19 (10.5%)15/19 (78.9%)
Infliximab 5mg/kg0/13 (0%)0/13 (0%)10/13 (76.9%)
Most frequent serious events
Most frequent serious events
EventOcrelizumab 200mgInfliximab 5mg/kg
INFECTIVE EXACERBATION OF CHRONIC OBSTRUCTIVE AIRWAYS DISEASERespiratory, thoracic and mediastinal disorders1/190/13
ENTERITISGastrointestinal disorders1/190/13
GASTROINTESTINAL HAEMORRHAGEGastrointestinal disorders1/190/13
RESPIRATORY FAILURERespiratory, thoracic and mediastinal disorders1/190/13
HUMERUS FRACTUREMusculoskeletal and connective tissue disorders1/190/13
Most frequent other events
Showing 10 of 48
Most frequent other events
EventOcrelizumab 200mgInfliximab 5mg/kg
RHEUMATOID ARTHRITISMusculoskeletal and connective tissue disorders0/193/13
UPPER RESPIRATORY TRACT INFECTIOnInfections and infestations4/191/13
SINUSITISInfections and infestations3/190/13
RASHSkin and subcutaneous tissue disorders3/190/13
NAUSEAGastrointestinal disorders2/192/13
CHILLSGeneral disorders1/192/13
HEADACHENervous system disorders0/192/13
HERPES ZOSTERInfections and infestations2/190/13
DIARRHOEAGastrointestinal disorders2/191/13
CYSTITISInfections and infestations0/191/13

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Ocrelizumab 200mgInfliximab 5mg/kgTotal
Mean53.5 ± 12.954.2 ± 15.253.83 ± 13.97
Sex: Female, Male
Sex: Female, Male(Participants)Ocrelizumab 200mgInfliximab 5mg/kgTotal
Female61016
Male9312
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ocrelizumab 200mgInfliximab 5mg/kgTotal
Hispanic or Latino112
Not Hispanic or Latino141226
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ocrelizumab 200mgInfliximab 5mg/kgTotal
American Indian or Alaska Native101
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American246
White12921
More than one race000
Unknown or Not Reported000
08

Study locations

53 sites
  • Rheumatology Associates
    Birmingham, Alabama 35205, United States
  • NEA Baptist Clinic
    Jonesboro, Arkansas 72401, United States
  • Dr. Brigid Freyne, MD
    Murrieta, California 92563, United States
  • Agilence Arthritis and Osteoporosis Medical Center, Inc.
    Whittier, California 90606, United States
  • Arthritis Assoc & Osteoporosis; Ctr of Colorado Springs
    Colorado Springs, Colorado 80920, United States
  • RASF-Clinical Research Center
    Boca Raton, Florida 33486, United States
  • Robert W. Levin MD - PP
    Dunedin, Florida 34698, United States
  • Science and Research Institute, Inc.
    Jupiter, Florida 33458, United States
  • Rheumatology Associates of Central Florida
    Orlando, Florida 32806, United States
  • Lovelace Scientific Resources
    Sarasota, Florida 34292, United States
  • Arthritis Res & Treatment
    Macon, Georgia 30281, United States
  • Harbin Clinic
    Rome, Georgia 30165, United States
  • Institute of Arthritis Research
    Idaho Falls, Idaho 83404, United States
  • Illinois Bone & Joint Inst.
    Morton Grove, Illinois 60053, United States
  • Springfield Clinic
    Springfield, Illinois 62703, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • Graves Gilbert Clinic
    Bowling Green, Kentucky 42101, United States
  • Clinical Pharmacology Study Group
    Worcester, Massachusetts 01610, United States
  • Hurley Medical Center
    Flint, Michigan 48503, United States
  • Rheumatology, P.C.; Medical Arts Building
    Kalamazoo, Michigan 49009, United States
  • Fiechtner Research Inc
    Lansing, Michigan 48910, United States
  • Shores Rheumatology
    Saint Clair Shores, Michigan 48081, United States
  • Jackson Arthritis Clinic
    Flowood, Mississippi 39232, United States
  • Arthritis Associates of Mississippi
    Jackson, Mississippi 39202, United States
  • Private Practice - Rosenberg
    Florissant, Missouri 63031, United States
  • Clayton Medical Research
    Saint Louis, Missouri 63117, United States
  • Billings Clinic; Research Center
    Billings, Montana 59101, United States
  • Billings Clinic
    Billings, Montana 59102, United States
  • Westroads Medical Group
    Omaha, Nebraska 68114, United States
  • Arthritis Center of Reno
    Reno, Nevada 89502, United States
  • Dartmouth-Hitchcock Medical Center, Rheumatology 5C
    Lebanon, New Hampshire 03756, United States
  • Regional Clinical Research
    Binghamton, New York 13905, United States
  • Arthritis & Osteoporosis Center
    Brooklyn, New York 11201, United States
  • Southern Tier Arthritis & Rheumatism
    Olean, New York 14760, United States
  • Buffalo Rheumatology Associates
    Orchard Park, New York 14127, United States
  • Barada,Harrell,Toohey&Bellhorn
    Durham, North Carolina 27704, United States
  • Physicians East Pa
    Greenville, North Carolina 27834, United States
  • Ohio State Univ Med Center
    Columbus, Ohio 43210, United States
  • Oklahoma Medical Research Foundation
    Oklahoma City, Oklahoma 73104, United States
  • Healthcare Research Consultants
    Tulsa, Oklahoma 74135, United States
  • Providence Arthritis Center
    Portland, Oregon 97213, United States
  • Lehigh Valley Physicians Group
    Allentown, Pennsylvania 18103, United States
  • Arthritis Associates
    Erie, Pennsylvania 16508, United States
  • Columbia Arthritis Center (Partnership Practice)
    Columbia, South Carolina 29204, United States
  • Piedmont Arthritis Clinic
    Greenville, South Carolina 29601, United States
  • South Carolina Research Center
    Myrtle Beach, South Carolina 29572, United States
  • Arthritis Associates
    Hixson, Tennessee 37343, United States
  • Ramesh Gupta - PP
    Memphis, Tennessee 38119, United States
  • Ctr for Inflammatory Disease
    Nashville, Tennessee 37205, United States
  • Amarillo Center For Clinical Research
    Amarillo, Texas 79124, United States
  • Phillip A Waller MD, PA
    Houston, Texas 77034, United States
  • Southwest Rheumatology
    Mesquite, Texas 75150, United States
  • Texas Arthritis Research Center
    San Antonio, Texas 78217, United States
09

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/members/ourmembers/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2009 to primary completion in Nov 2012, 44 months.

Results were first posted in Nov 2020, 7 years 11 months after primary completion. A results delay was requested in Jan 2014.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2008
First posted
Dec 15, 2008
StartActual
Mar 5, 2009
Primary completionActual
Nov 14, 2012
CompletionActual
Nov 14, 2012
Results delay requested
Jan 27, 2014
Results first posted
Nov 6, 2020
Last update
Nov 6, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 6, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00808210
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Dec 15, 2008
Start date
Mar 5, 2009
Primary completion
Nov 14, 2012
Completion
Nov 14, 2012
Results posted
Nov 6, 2020
Last update
Nov 6, 2020

Study contacts

Clinical Trials
study director · Genentech, Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ocrelizumab

Start the discussion